| INTRODUC TI ONIn the history of modern transplantation and transplantation immunology, skin grafting has had a special place since the initial scientific studies of T. Gibson and P. Medawar involving human skin allografts during World War II. 1 Indeed, the analysis of human skin allograft rejection in a patient with extensive burns indicated that human tissue rejection was an immunologic phenomenon. These observations were undoubtedly a key stimulus for P. Medawar and others to subsequently develop the entire field of transplantation immunology.Currently, total skin allografts are generally considered vascularized composite allotransplantation (VCA). [2][3][4][5] The normal epidermis has numerous dendritic cells, which play a significant role in rejection. 3 This characterizes the skin as one of the most immunogenic tissues and VCA as one of the most challenging types of allografts, 2,3,5 and skin allografts are virtually always rejected unless adequate long-term immunosuppression is administered. 2,6 With current immunosuppressive regimens, solid organ transplantation (SOT) rejections are currently relatively well controlled, but the development of circulating anti-HLA donor-specific antibody (DSA) in the recipient plays a major role in the late loss of SOT. 7,8 VCA has emerged as a possible option to treat patients who have lost their arms, face, or who have had large body skin defects. 2,9 The management of the recipients after VCA includes skin biopsies, and grades of rejection are diagnosed according to the Banff classification. 10